Stockscreener 앱 받기
4.97
1.64%
0.08
전일 마감가:
$4.89
열려 있는:
$4.9
하루 거래량:
293.73K
Relative Volume:
0.54
시가총액:
$274.63M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
94.85
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
+3.11%
1개월 성능:
+13.21%
6개월 성능:
+2.47%
1년 성능:
-7.28%
1일 변동 폭
$4.86
$5.04
1주일 범위
$4.66
$5.04
52주 변동 폭
$3.8092
$6.365
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.97 | 274.63M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus
DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus
Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus
Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
Vanda Approves Key Proposals at Annual Meeting - TipRanks
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow
Mystics enter new partnership with Vanda Pharmaceuticals - Monumental Sports Network
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - The Malaysian Reserve
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News - GuruFocus
Mystics tap D.C.'s Vanda Pharmaceuticals as new jersey sponsor - The Business Journals
Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports
Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Can - GuruFocus
Vanda Pharmaceuticals (VNDA) Projected to Transform with Overwei - GuruFocus
Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald - TipRanks
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union | Libero Quotidiano.it - Libero Quotidiano
Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Vanda: Q1 Earnings Snapshot - MySA
Vanda Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats - GuruFocus
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2025 forecasts - Investing.com
Capitals Announce Game 3 Watch Party at The Wharf as Part of Additional Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats Estimate, Revenue Surpasses Forecast at $50 Million - GuruFocus
Vanda Pharmaceuticals (VNDA) Reports Strong Q1 Revenue and Expands Product Pipeline | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - StreetInsider
HC Wainwright & Co. Reiterates Buy Rating on Vanda Pharmaceutica - GuruFocus
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):